<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02983019</url>
  </required_header>
  <id_info>
    <org_study_id>ISIM-LCR</org_study_id>
    <nct_id>NCT02983019</nct_id>
  </id_info>
  <brief_title>Treatment of Influenza in Routine Clinical Practice</brief_title>
  <acronym>FLU-EE</acronym>
  <official_title>Non-interventional Study: Treatment of Influenza in Routine Clinical Practice (FLU-EE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nearmedic Plus LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nearmedic Plus LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the statistics of influenza and acute respiratory viral infections&#xD;
      (ARVI) management in outpatient sites in Russia, Armenia, Moldova and Georgia (epidemiology:&#xD;
      disease severity and bacterial exacerbations; patients demography; treatment duration and&#xD;
      timelines; safety; quality of treatment) in routine clinical practice with focus on drug&#xD;
      therapy and usage of interferons' inducers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This non-interventional study covers more than 15000 patients from outpatient sites in&#xD;
      Russia, Armenia, Moldova and Georgia.&#xD;
&#xD;
      Influenza and acute respiratory viral infections (ARVI) diagnosis validate according to&#xD;
      &quot;World Health Organization (WHO) Guidelines for Pharmacological Management of Pandemic&#xD;
      Influenza A (H1N1) 2009 and other Influenza Viruses&quot;. All patients' examinations are carried&#xD;
      out according to the local routine clinical practice and local and international standards of&#xD;
      care.&#xD;
&#xD;
      The following data will be collected and analyzed after the end of treatment:&#xD;
&#xD;
        -  demography&#xD;
&#xD;
        -  disease severity&#xD;
&#xD;
        -  body temperature&#xD;
&#xD;
        -  chills and fever (no/mild/severe)&#xD;
&#xD;
        -  weakness (no/mild/severe)&#xD;
&#xD;
        -  muscle or joint pain (no/mild/severe)&#xD;
&#xD;
        -  rhinitis (yes/no)&#xD;
&#xD;
        -  throat irritation (no/mild/severe)&#xD;
&#xD;
        -  headache (no/mild/severe)&#xD;
&#xD;
        -  cough (no/mild/severe)&#xD;
&#xD;
        -  conjunctivitis (no/mild/severe)&#xD;
&#xD;
        -  timelines: disease onset, first visit to physician, start of treatment&#xD;
&#xD;
        -  therapy (drug name, dose, with focus on interferons' inducers)&#xD;
&#xD;
        -  bacterial exacerbations (yes/no)&#xD;
&#xD;
        -  therapy of bacterial exacerbations (drug name)&#xD;
&#xD;
        -  adverse events&#xD;
&#xD;
        -  results of treatment satisfaction questionnaire for medication (TSQM-9), if completed by&#xD;
           patient&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The socio-demographic data and symptoms of disease in the joint population of patients with influenza and influenza-like illness caused by different types of viruses</measure>
    <time_frame>up to 14 days</time_frame>
    <description>socio-demographic data, symptoms of disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The treatment description: names of drugs, dose, time of administration with regards to disease onset (&quot;early&quot; - from 1 to 3 days of symptoms; &quot;late&quot; - 4 or more days of symptoms)</measure>
    <time_frame>up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The efficacy (yes or no) of the treatment schemas with regards to severity of disease (mild, moderate, severe)</measure>
    <time_frame>up to 14 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of influenza complications with antibacterial drugs administration requirement</measure>
    <time_frame>up to 14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events (AE) with regards to type and severity of AE (mild, moderate, severe; according to physician's opinion)</measure>
    <time_frame>up to 14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-influenza treatment schemas satisfaction rate according to TSQM-9 questionnaire (if completed by patient)</measure>
    <time_frame>up to 14 days</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">18946</enrollment>
  <condition>Influenza</condition>
  <condition>Acute Upper Respiratory Infection</condition>
  <arm_group>
    <arm_group_label>Therapy with interferons' inducers</arm_group_label>
    <description>Therapy according to routine practice (including Kagocel) Groups will be splitted during the final data analysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Therapy without interferons' inducers</arm_group_label>
    <description>Therapy according to routine practice Groups will be splitted during the final data analysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kagocel</intervention_name>
    <description>Investigators could prescribe other drugs in frame of routine clinical practice</description>
    <arm_group_label>Therapy with interferons' inducers</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with confirmed diagnosis of influenza or influenza-like illness caused by a&#xD;
        different type of virus which are on anti-flu therapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients â‰¥ 18 years old,&#xD;
&#xD;
          -  patients diagnosed with influenza or influenza-like illness caused by a different type&#xD;
             of virus,&#xD;
&#xD;
          -  patients to whom anti-flu treatment administered,&#xD;
&#xD;
          -  patients who have signed informed consent for management of their personal data.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  no exclusion criteria except participating in a current clinical trial because of&#xD;
             non-interventional sudy design&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivan Sitnikov, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yaroslavl State Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yerevan State Medical University after M. Heratsi</name>
      <address>
        <city>Yerevan</city>
        <zip>0025</zip>
        <country>Armenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vl.Bakhutashvili Institute of Medical Biotechnology of Tbilisi State Medical University</name>
      <address>
        <city>T'bilisi</city>
        <zip>01059</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State University of Medicine and Pharmacy Nicolae Testemitanu</name>
      <address>
        <city>Kishinev</city>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kazan State Medical University</name>
      <address>
        <city>Kazan'</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Armenia</country>
    <country>Georgia</country>
    <country>Moldova, Republic of</country>
    <country>Russian Federation</country>
  </location_countries>
  <results_reference>
    <citation>Fazylov VK, Sitnikov IG, Silina EV, Shevchenko SB, Mozhina LN, Zamyatina LL, Yeganyan GA, Groppa LG, Korsantia BM. [Treatment for acute respiratory viral infection and influenza in daily clinical practice: Results of the multicenter international observational FLU-EE study]. Ter Arkh. 2016;88(11):68-75. doi: 10.17116/terarkh2016881168-75. Russian.</citation>
    <PMID>28005034</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>November 24, 2016</study_first_submitted>
  <study_first_submitted_qc>December 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2016</study_first_posted>
  <last_update_submitted>February 16, 2017</last_update_submitted>
  <last_update_submitted_qc>February 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>influenza</keyword>
  <keyword>flu</keyword>
  <keyword>acute respiratory viral infection</keyword>
  <keyword>ARVI</keyword>
  <keyword>acute upper respiratory infection</keyword>
  <keyword>AURI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

